肿瘤来源的IgG抑制脐带血中T细胞的增殖

doi:10.3969/j.issn.1671-167X.2017.05.014

摘要/Abstract

摘要： 目的探究肿瘤来源的IgG是否对T细胞活化具有抑制作用。方法首先从卵巢癌肿瘤组织纯化了肿瘤来源的IgG(tumor derived IgG, tIgG),并从脐带血中分离出单个核细胞(cord blood mononuclear cells,CBMC)及淋巴细胞(cord blood lymphocyte,CBL),用植物血球凝集素(phytohaemagg lutinin,PHA)刺激单个核细胞和淋巴细胞,使单个核细胞与淋巴细胞处于增殖状态,用荧光染料羟基荧光素二醋酸盐琥珀酰亚胺酯(carboxyfluorescein succinimidyl amino ester,CFSE)染色,CFSE对细胞无毒性,可以穿透细胞膜,在活细胞内与胞内蛋白结合,其荧光强度会随着细胞的分裂增殖而逐级递减,从而可以检测细胞增殖的情况。把从卵巢癌肿瘤组织中纯化得到的tIgG分为1 mg/L、10 mg/L和100 mg/L组,分别加入到单个核细胞和淋巴细胞中,静脉注射用免疫球蛋白(intravenous immunoglo-bulin,IVIG)作为阳性对照,也分为1 mg/L、10 mg/L和100 mg/L组,磷酸缓冲盐溶液(phosphate buffer saline,PBS)作为阴性对照,用细胞流式术检测CD4⁺及CD8⁺ T细胞的增殖能力,并分别在64 h和86 h两个时间点检测细胞的增殖情况。结果在CBMC体系中加入的tIgG可以明显地抑制CBMC中T细胞的增殖,发挥免疫抑制作用;同样,在CBL体系中加入的tIgG对T细胞也有抑制作用,且加入tIgG刺激的T细胞比加入IVIG刺激的T细胞的抑制增殖作用更强;在CBL体系中,tIgG的1 mg/L组和10 mg/L组对T细胞发挥的抑制增殖作用比100 mg/L组弱。结论 tIgG可以抑制T细胞的增殖,促使肿瘤发挥肿瘤免疫逃逸效应。

关键词: 免疫球蛋白G, 免疫逃逸, 肿瘤, T淋巴细胞

Abstract: Objective: To explore the function of tumor derived IgG (tIgG) and whether the tIgG can inhibit T cells activity. Methods: The tIgG was purified from ovarian cancer tissue. The cord blood monocyte cells (CBMC) and cord blood lymphocyte (CBL) were isolate from human umbilical cord blood. The CBMC and CBL were stimulated with phytohaemagg lutinin (PHA) in order to let the CBMC and CBL in the state of proliferation. Carboxyfluorescein succinimidyl amino ester (CFSE) was cultured with CBMC and CBL. CFSE had no cell toxicity, which could penetrate through the cell membrane and combine the intracellular protein. The fluorescence intensity decreased with the proliferation of cells step by step, so the proliferation of these cells could be detected in flow ctytometry. The tIgG which was purified from ovarian cancer tissue was divided into three groups, 1 mg/L group, 10 mg/L group, and 100 mg/L group, and the intravenous immunoglobulin (IVIG) was also divided into three groups too. The CBMC and CBL were treated by tIgG with 1 mg/L, 10 mg/L, and 100 mg/L in order to observe the proliferation of T cells. The cells were treated with IVIG as a positive control group, and the cells were treated with phosphate buffer saline (PBS) as a negative control. The proliferation of CD4⁺ or CD8⁺ T cells were detected in CBMC and CBL. The proliferation of the T cells in CBMC and CBL after 64 h and 86 h were detected. Results: In the system of CBMC, the tIgG could suppress the proliferation of CD4⁺ or CD8⁺ T cells. The results could also be found in the system of CBL. The CD4⁺ or CD8⁺ T cells in the group which were treated with PBS were more active than those in the group which were treated with tIgG and IVIG. The suppression in the group which were treated with tIgG, was stronger than that in the group treated with IVIG. In addition, the suppression of T cells in the group which were stimulated with tIgG as 100 mg/L was more effective than that in the group which were stimulated with tIgG as 10 mg/L. This could prove that tIgG had the function of immunomodulation. Conclusion: The tIgG can be involved in immune escape of cancer.

Key words: Immunoglobulin G, Immune escape, tumor, T-lymphocytes

中图分类号:

R392.12

刘恩阳, 刘静芳, 邵文威, 肖琳, 李国辉, 昌晓红, 邱晓彦. 肿瘤来源的IgG抑制脐带血中T细胞的增殖[J]. 北京大学学报(医学版), 2017, 49(5): 824-828.

LIU En-yang, LIU Jing-fang, SHAO Wen-wei, XIAO Lin, LI Guo-hui, CHANG Xiao-hong, QIU Xiao-yan. Tumor derived IgG suppress the proliferation of T cells in cord blood[J]. Journal of Peking University(Health Sciences), 2017, 49(5): 824-828.

参考文献

[1] 陈玉强, 王元. 丙种免疫球蛋白Fc段糖基化及其生物学活性和功能[J]. 现代生物医学进展, 2008, 8(7): 1368-1370.
[2] Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc [J]. Science, 2008, 320(5874): 373-376.
[3] 邱晓彦, 杨贵贞. 恶性肿瘤细胞内呈现的Ig样蛋白特性及Ig基因结构分析[J]. 中国免疫学杂志, 1996, 20(5): 296-297.
[4] Liao Q , Liu W, Liu Y, et al. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis [J]. Oncotarget, 2015, 6(37): 40081-40094.
[5] 邱晓彦, 杨贵贞. 恶性肿瘤细胞内存在免疫球蛋白样物质[J]. 白求恩医科大学学报, 1996, 22(6): 572-573.
[6] 邱晓彦, 侯春梅, 李秀森, 等. Ig样物质存在于多种肿瘤传代细胞[J]. 癌症, 1999, 18(1): 180-184.
[7] Qiu X, Zhu X, Zhang L, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells [J]. Cancer Res, 2003, 63(19): 6488-6495.
[8] Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus [J]. Arthritis Rheum, 2003, 48(12): 3497-3502.
[9] Rogozin IB, Iyer LM, Liang L, et al. Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase [J]. Nat Immunol, 2007, 8(6): 647-656.
[10] Herrin BR, Alder MN, Roux KH, et al. Structure and specificity of lamprey monoclonal antibodies [J]. Proc Natl Acad Sci USA, 2008, 105(6): 2040-2045.
[11] Pancer Z, Amemiya CT, Ehrhardt GR, et al. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey [J]. Nature, 2004, 430(6996): 174-180.
[12] Tha-In T, Metselaar HJ, Tilanus HW, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors [J]. Transplantation, 2006, 81(12): 1725-1734.
[13] Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin [J]. Clin Immunol Immunopathol, 1997, 83(1): 77-85.
[14] Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin [J]. Clin Immunol Immunopathol, 1994, 73(2): 180-186.
[15] De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes” [J]. Blood, 2008, 112(8): 3303-3311.
[16] Vogelaar L, Van’t Spijker A, Vogelaar T, et al. Solution focused therapy: a promising new tool in the management of fatigue in Crohn’s disease patients psychological interventions for the management of fatigue in Crohn’s disease [J]. J Crohns Colitis, 2011, 5(6): 585-591.
[17] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation [J]. Science, 2006, 313(5787): 670-673.
[18] Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins [J]. Annu Rev Immunol, 2007(25): 21-50

相关文章 15

[1]	李志存, 吴天俣, 梁磊, 范宇, 孟一森, 张骞. 穿刺活检单针阳性前列腺癌术后病理升级的危险因素分析及列线图模型构建[J]. 北京大学学报（医学版）, 2024, 56(5): 896-901.
[2]	刘家骏, 刘国康, 朱玉虎. 免疫相关性重症肺炎1例[J]. 北京大学学报（医学版）, 2024, 56(5): 932-937.
[3]	黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报（医学版）, 2024, 56(4): 557-561.
[4]	田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报（医学版）, 2024, 56(4): 567-574.
[5]	姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报（医学版）, 2024, 56(4): 575-581.
[6]	欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588.
[7]	王滨帅,邱敏,张前进,田茂锋,刘磊,王国良,陆敏,田晓军,张树栋. 6例肾尤文肉瘤伴静脉瘤栓的诊治[J]. 北京大学学报（医学版）, 2024, 56(4): 636-639.
[8]	虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 661-666.
[9]	舒帆,郝一昌,张展奕,邓绍晖,张洪宪,刘磊,王国良,田晓军,赵磊,马潞林,张树栋. 肾部分切除术治疗囊性肾癌的功能学和肿瘤学结果：单中心回顾性研究[J]. 北京大学学报（医学版）, 2024, 56(4): 667-672.
[10]	方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报（医学版）, 2024, 56(4): 741-744.
[11]	柴晓东,孙子文,李海爽,朱靓怡,刘小旦,刘延涛,裴斐,常青. 髓母细胞瘤分子亚型中CD8⁺T淋巴细胞浸润的临床病理特点[J]. 北京大学学报（医学版）, 2024, 56(3): 512-518.
[12]	林国中,马长城,吴超,司雨,杨军. 微通道技术在颈椎管肿瘤微创切除术中的应用[J]. 北京大学学报（医学版）, 2024, 56(2): 318-321.
[13]	俞光岩. 儿童唾液腺疾病[J]. 北京大学学报（医学版）, 2024, 56(1): 1-3.
[14]	薛蔚,董樑,钱宏阳,费笑晨. 前列腺癌新辅助治疗与辅助治疗的现状及进展[J]. 北京大学学报（医学版）, 2023, 55(5): 775-780.
[15]	薛子璇,唐世英,邱敏,刘承,田晓军,陆敏,董靖晗,马潞林,张树栋. 青年肾肿瘤伴瘤栓的临床病理特征及预后分析[J]. 北京大学学报（医学版）, 2023, 55(5): 802-811.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed